Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger
will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.


Carolinas HealthCare System

Research and Clinical Trials

Title  
Optimum/AC-058B301
Brief Description  
Subjects 18 to 55 years of age will be randomly assigned to take ponesimod or teriflunomide (Aubagio) pills daily; they have an equal chance of getting either treatment. The treatment will last for 108 weeks. An end-of-treatment visit will take place at Week 108. All subjects will enter the safety follow-up period (2 to 4 weeks). For an individual subject, the maximum duration of the study will be approximately 118 weeks (2.2 years).
Who may be Eligible  
People 18-55 years of age with relapsing forms of multiple sclerosis
Start Date  
08/05/2015
IRB Number  
08-15-09A
Principal Investigator  
Conway, Jill
Contact Name  
Maryanne

For More Information, Contact   Maryanne  Burdette , RN
Phone:  (704) 446-1925  Fax:  (704) 446-0840 
Email:  Maryanne.burdette@carolnashealthcare.org
Address:  Neurosciences Institute: Neurology-Charlotte
Close